FeesSafety
Pluang+

Moderna surges on cancer vaccine hopes; BioNTech faces leadership changes and slower growth.

Market News
20 Nov 2026, 10:55 WIB
The Motley Fool
View Source
Bullish
Moderna surges on cancer vaccine hopes; BioNTech faces leadership changes and slower growth.

Moderna and BioNTech, once known for their COVID-19 vaccines, are shifting focus to cancer treatments. Moderna's stock has risen due to promising results from its personalized cancer vaccine, intismeran, which is in multiple phase 3 trials and showing strong potential. BioNTech, despite a robust pipeline and significant cash reserves, faces leadership changes and slower stock performance as it awaits new product approvals. Moderna's growing sales and upcoming regulatory milestones make it a more attractive investment heading into 2027.

Moderna (MRNA) shares are priced at USD 197.68 on Pluang as of Nov 20, 2026 16:01 WIB, showing a slight 0.83% decline in the last day. BioNTech (BNTX) trades at USD 80.59 with a 0.97% drop over the same period. Despite the recent selling pressure on Moderna with 96% of orders being sell orders, BioNTech sees a more balanced order activity with 53% buy orders on Pluang.

More News (MRNA)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App